McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Is McKesson (MCK) Undervalued As Portfolio Changes And Higher Guidance Refocus Growth? - simplywall.st

AI-generated analysis

πŸ“ˆ McKesson has raised its fiscal 2027 outlook following a strategic refocus on core business growth.

πŸ”„ The company is executing portfolio changes including an exit from Canada and Norway to streamline operations.

πŸ₯ McKesson plans to spin off its Medical-Surgical unit to concentrate resources on high-margin segments.

πŸ’Š Recent acquisitions of Core Ventures and PRISM Vision are expanding the provider network and service portfolio.

πŸ“‰ The stock has delivered a 22.61% return over the last 90 days and a 31.62% one-year total shareholder return.

🎯 Analyst fair value estimates suggest a target price of $980.80, implying the stock is undervalued at current levels.

πŸ‡ΊπŸ‡Έ The portfolio is being reshaped to lean more heavily into U.S. pharmaceuticals and oncology services.

βš–οΈ Strategic shifts aim to improve revenue mix quality and drive higher operating margins over time.

Bullish Signals
  • McKesson has raised its fiscal 2027 outlook, signaling confidence in future earnings power and cash returns.
  • The company is increasing adoption of specialty and oncology pharmaceuticals to improve revenue mix quality.
  • Recent acquisitions of Core Ventures and PRISM Vision are expanding the provider network and service portfolio.
  • Strategic portfolio changes including exits from international markets aim to focus on core U.S. businesses.
  • The planned spin-off of the Medical-Surgical unit is intended to sharpen focus on higher-margin segments.
  • McKesson is pursuing disciplined share count reduction which supports a potential stock rerating.
Risk Factors
  • Investors must monitor ongoing policy pressure on drug pricing which could impact revenue growth.
  • There is a risk that distributors or payers may bring more volume in-house, challenging McKesson's distribution thesis.
Full Analysis
McKesson (MCK) has regained investor attention following strategic portfolio changes, including its exit from Canada and Norway, and the planned spin-off of its Medical-Surgical unit. These moves are accompanied by a raised fiscal 2027 outlook, signaling a refocus on core growth drivers within the U.S. market. The company is shifting its portfolio to lean more heavily into U.S. pharmaceuticals and oncology services. This strategic pivot aims to improve the quality of its revenue mix and position the business for higher operating margins and sustained earnings growth through recent acquisitions like Core Ventures and PRISM Vision. Simply Wall Street analysis suggests McKesson is currently undervalued with a fair value target of $980.80, compared to a recent closing price near $906. The narrative highlights potential upside driven by specialty pharmaceutical growth, disciplined share count reduction, and the rerating of the stock based on improved fundamentals.